If you’re eyeing Biotest and wondering whether now is the right moment to buy, hold, or move on, you’re in good company. The stock has been resting at €28.4, and though its short-term moves have been ...
Spanish plasma-based medicines producer Grifols announced that Yimmugo, an innovative intravenous immunoglobulin (IVIg) ...
This document is not, and should not be regarded asinvestment advice or a recommendation, regarding any particular investment. As at the date of publication, the author has a long or short position in ...
eieich, March 31, 2025: Biotest AG (ISIN DE0005227201, ISIN DE0005227235) has today concluded a delisting agreement with its major shareholder, Grifols, S.A., which holds approximately 97.14 % of the ...
Management Board examines whether the request meets the legal requirements Proposed resolution on the conversion of Biotest AG into Biotest GmbH & Co. KGaA Dreieich, 4 August 2025. Biotest AG hereby ...
BARCELONA, Spain, July 01, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols ...
BOCA RATON, Fla., Dec. 4 /PRNewswire/ -- Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, today announced that it has completed the acquisition of the ...
Biotest Pharmaceuticals has sold its U.S. therapy business, which includes its Boca Raton headquarters and plasma production center, to ADMA Biologics of Ramsey, N.J. The $40 million deal gives ...
Dreieich, 19 September 2025. Biotest AG announces that, after careful consideration, the Management Board has deemed admissible the request received in writing from Grifols S.A. on 1 August 2025 ...
Dreieich, June 24, 2015. Biotest AG today announced that AbbVie and Biotest will end their collaboration on the development and commercialisation of Tregalizumab (BT-061). AbbVie has exercised its ...
A Colorado Springs company claims to have achieved a milestone with the release of an exercise supplement its says can bind (block) a key protein that limits growth of new muscle cells. But a Johns ...
FRANKFURT (Reuters) - Germany's Biotest has agreed to be bought by Chinese investor Creat Group Corp in a cash deal valuing the blood plasma products maker at 1.3 billion euros ($1.4 billion), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback